{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:53:42Z","timestamp":1790538822492,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.beha.2017.11.001","type":"journal-article","created":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T01:02:52Z","timestamp":1510707772000},"page":"57-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Overview on the management of non-gastric MALT lymphomas"],"prefix":"10.1016","volume":"31","author":[{"given":"Irene","family":"Defrancesco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9504-991X","authenticated-orcid":false,"given":"Luca","family":"Arcaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.beha.2017.11.001_bib1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncr.27773","article-title":"Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database","volume":"119","author":"Olszewski","year":"2013","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.beha.2017.11.001_bib2","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2002-04-1279","article-title":"International Extranodal Lymphoma Study Group. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue","volume":"101","author":"Zucca","year":"2003","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2017.11.001_bib3","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood-2015-12-624304","article-title":"The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance","volume":"127","author":"Zucca","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2017.11.001_bib4","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/sj.leu.2404782","article-title":"MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course","volume":"21","author":"W\u00f6hrer","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2017.11.001_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.semcancer.2013.11.005","article-title":"Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type","volume":"24","author":"Thieblemont","year":"2014","journal-title":"Semin Cancer Biol"},{"issue":"8","key":"10.1016\/j.beha.2017.11.001_bib6","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/jnci\/djh102","article-title":"Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas","volume":"96","author":"Ferreri","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.beha.2017.11.001_bib7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0046-8177(00)80233-6","article-title":"Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin","volume":"31","author":"Roggero","year":"2000","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.beha.2017.11.001_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa031887","article-title":"Immunoproliferative small intestinal disease associated with Campylobacter jejuni","volume":"350","author":"Lecuit","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.beha.2017.11.001_bib9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/bjh.12703","article-title":"Prevalence of Achromobacter xylosoxidans in pulmonary mucosa-associated lymphoid tissue lymphoma in different regions of Europe","volume":"164","author":"Adam","year":"2014","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.beha.2017.11.001_bib10","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdl388","article-title":"Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT","volume":"18","author":"Arcaini","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2017.11.001_bib11","first-page":"638185","article-title":"Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy","author":"Arcaini","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.beha.2017.11.001_bib12","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/asheducation-2014.1.590","article-title":"Hepatitis C virus-associated B-cell non-Hodgkin lymphomas","volume":"2014","author":"Vannata","year":"2014","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.beha.2017.11.001_bib13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s11899-014-0218-1","article-title":"Clinical aspects of Malt lymphomas","volume":"9","author":"Kalpadakis","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"21","key":"10.1016\/j.beha.2017.11.001_bib14","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.1158\/1078-0432.CCR-04-0803","article-title":"Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphoma","volume":"10","author":"W\u00f6hrer","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.beha.2017.11.001_bib15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajh.20157","article-title":"Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement","volume":"77","author":"Asatiani","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2017.11.001_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1634\/theoncologist.11-3-285","article-title":"Nongastric marginal-zone B-Cell MALT lymphoma: prognostic value of disease dissemination","volume":"11","author":"Arcaini","year":"2006","journal-title":"Oncol"},{"key":"10.1016\/j.beha.2017.11.001_bib17","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2017.11.001_bib18","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.beha.2017.11.001_bib19","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V95.3.802.003k19_802_806","article-title":"Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed","volume":"95","author":"Thieblemont","year":"2000","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.beha.2017.11.001_bib20","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1200\/JCO.2006.06.0723","article-title":"Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience","volume":"24","author":"Raderer","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2017.11.001_bib21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3324\/haematol.11835","article-title":"Dissemination patterns in non-gastric MALT lymphoma","volume":"93","author":"De Boer","year":"2008","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.beha.2017.11.001_bib22","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1080\/10428190802510331","article-title":"Non-gastric extra-nodal marginal zone lymphomas \u2013 a single centre experience on 76 patients","volume":"49","author":"Kalpadakis","year":"2008","journal-title":"Leukemia Lymphoma"},{"issue":"7","key":"10.1016\/j.beha.2017.11.001_bib23","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3324\/haematol.2011.040402","article-title":"Genomic profiles of MALT lymphomas: variability across anatomical sites","volume":"96","author":"Kwee","year":"2011","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.beha.2017.11.001_bib24","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1634\/theoncologist.2015-0180","article-title":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a multicenter, international experience of 248 patients (IELSG 41)","volume":"20","author":"Jackson","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.beha.2017.11.001_bib25","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","article-title":"A\u00a0MALT lymphoma prognostic index generated from the dataset of the IELSG-19 prospective clinical trial","volume":"130","author":"Thieblemont","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.001_bib26","series-title":"NCCN clinical practice guidelines in oncology","year":"2014"},{"issue":"8","key":"10.1016\/j.beha.2017.11.001_bib27","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2013-02-486522","article-title":"Antibiotic therapy in non gastrointestinal MALT lymphoma: a review of the literature","volume":"122","author":"Kiesewetter","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2017.11.001_bib28","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00277-014-2042-z","article-title":"Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis","volume":"93","author":"W\u00f6hrer","year":"2014","journal-title":"Ann Hematol"},{"issue":"22","key":"10.1016\/j.beha.2017.11.001_bib29","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1200\/JCO.2003.06.085","article-title":"Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome","volume":"21","author":"Tsang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.beha.2017.11.001_bib30","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/cncr.25226","article-title":"Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy","volume":"116","author":"Goda","year":"2010","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.beha.2017.11.001_bib31","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of Rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2017.11.001_bib32","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1200\/JCO.1995.13.10.2524","article-title":"Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression","volume":"13","author":"Hammel","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2017.11.001_bib33","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/annonc\/mdg492","article-title":"Treatment of extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP)","volume":"14","author":"W\u00f6hrer","year":"2003","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.beha.2017.11.001_bib34","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study","volume":"31","author":"Zucca","year":"2013","journal-title":"JCO"},{"issue":"3","key":"10.1016\/j.beha.2017.11.001_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(14)00021-0","volume":"1","author":"Salar","year":"2014","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.beha.2017.11.001_bib36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.beha.2016.07.005","article-title":"Clinical futures and management of non gastric non-ocular extranodal mucosa associated lymphoid tissue (ENMALT) marginal zone lymphomas","author":"Matutes","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.beha.2017.11.001_bib37","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/cncr.20237","article-title":"Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma","volume":"100","author":"Zinzani","year":"2004","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.beha.2017.11.001_bib38","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1002\/cncr.24605","article-title":"Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue type","volume":"115","author":"Salar","year":"2009","journal-title":"Cancer"},{"issue":"1\u20132","key":"10.1016\/j.beha.2017.11.001_bib39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.beha.2016.11.002","article-title":"Ocular adnexal marginal zone lymphoma: clinical presentation, pathogenesis, diagnosis, prognosis, and treatment","volume":"30","author":"Sassone","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"issue":"12","key":"10.1016\/j.beha.2017.11.001_bib40","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.beha.2017.11.001_bib41","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2012.065995","article-title":"A\u00a0phase II study of lenalidomide in patients with extranodal marginal zone B cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma)","volume":"98","author":"Kiesewetter","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2017.11.001_bib42","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2016-06-720599","article-title":"A\u00a0phase II study of rituximab plus lenalidomide for mucosa associated lymphoid tissue lymphoma (MALT lymphoma)","volume":"129","author":"Kiesewetter","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2017.11.001_bib43","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2015-0176","article-title":"Delayed efficacy after treatment with lenalidomide or thalidomide in patients with mucosa-associated lymphoid tissue lymphoma","volume":"21","author":"Kiesewetter","year":"2016","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.beha.2017.11.001_bib44","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/annonc\/mdq416","article-title":"International extranodal lymphoma study group. Clinical activity of bortezomib in relapsed\/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)","volume":"22","author":"Conconi","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2017.11.001_bib45","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.001_bib46","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting BTK with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.001_bib47","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2017.11.001_bib48","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/annonc\/mdm513","article-title":"Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy","volume":"19","author":"Ferreri","year":"2008","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.beha.2017.11.001_bib49","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/jnci\/djj373","article-title":"Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial","volume":"98","author":"Ferreri","year":"2006","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"24","key":"10.1016\/j.beha.2017.11.001_bib50","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2011.41.4466","article-title":"Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial","volume":"30","author":"Ferreri","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.001_bib51","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.radonc.2005.11.005","article-title":"Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy","volume":"78","author":"Ejima","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.beha.2017.11.001_bib52","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.ophtha.2006.01.057","article-title":"Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit","volume":"113","author":"Ben Simon","year":"2006","journal-title":"Ophtalmology"},{"issue":"2","key":"10.1016\/j.beha.2017.11.001_bib53","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2141.2010.08179.x","article-title":"Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial","volume":"150","author":"Govi","year":"2010","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.beha.2017.11.001_bib54","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3322\/caac.21330","article-title":"Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associate lymphoid tissue (MALT lymphoma)","volume":"66","author":"Raderer","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.beha.2017.11.001_bib55","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0167-8140(00)00328-5","article-title":"Orbital lymphoma: radiotherapy outcome and complications","volume":"59","author":"Stafford","year":"2001","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.beha.2017.11.001_bib56","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/028418601750288217","article-title":"Non-Hodgkin\u2019s lymphoma of the ocular adnexa","volume":"40","author":"Sasai","year":"2001","journal-title":"Acta Oncol"},{"key":"10.1016\/j.beha.2017.11.001_bib57","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s00417-003-0831-5","article-title":"Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases","volume":"242","author":"Coupland","year":"2004","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.beha.2017.11.001_bib58","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0360-3016(02)04159-7","article-title":"Outcome and prognostic factors in orbital lymphoma: a rare cancer network study on 90 consecutive patients treated with radiotherapy","volume":"55","author":"Martinet","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.beha.2017.11.001_bib59","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/annonc\/mdj025","article-title":"Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma","volume":"17","author":"Tanimoto","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2017.11.001_bib60","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1309\/AJCPNLC9NC9WTQYY","article-title":"Cutaneous B-Cell lymphoproliferative disorders. Report of the 2011 society for hematopathology\/European association for haematopathology workshop","volume":"139","author":"Swerdlow","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.beha.2017.11.001_bib61","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","article-title":"European organization for research and treatment of cancer and international society for cutaneous lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas","volume":"112","author":"Senff","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.001_bib62","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaad.2013.04.047","article-title":"Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients","volume":"69","author":"Servitje","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.beha.2017.11.001_bib63","first-page":"208","article-title":"Extranodal marginal zone lymphoma of the lung: evolution from an underlying reactive lymphoproliferative disorder","volume":"5","author":"Rubenstein","year":"2015","journal-title":"J\u00a0Clin Exp Pathol"},{"key":"10.1016\/j.beha.2017.11.001_bib64","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1183\/09031936.00039309","article-title":"Clinical characteristics and prognostic factors of pulmonary MALT lymphoma","volume":"34","author":"Zinzani","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.beha.2017.11.001_bib65","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1183\/09031936.00039309","article-title":"I.\u00a0Clinical characteristics and prognostic factors of Pulmonary MALT lymphoma","volume":"34","author":"Borie","year":"2009","journal-title":"Eur Resp J"},{"issue":"6","key":"10.1016\/j.beha.2017.11.001_bib66","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-009-0875-7","article-title":"Pulmonary marginal zone B-cell lymphoma of MALT type: what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study","volume":"89","author":"Oh","year":"2010","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.beha.2017.11.001_bib67","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/hon.2039","article-title":"Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens","volume":"31","author":"Zinzani","year":"2013","journal-title":"Hematol Oncol"},{"issue":"6","key":"10.1016\/j.beha.2017.11.001_bib68","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2004-07-2755","article-title":"Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms","volume":"105","author":"Al-Saleem","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2017.11.001_bib69","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3748\/wjg.v17.i6.697","article-title":"Primary gastrointestinal lymphoma","volume":"17","author":"Ghimire","year":"2011","journal-title":"World J Gastroenterol"},{"issue":"23","key":"10.1016\/j.beha.2017.11.001_bib70","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.3938.3938","article-title":"Anti-lymphoma activity of interferon-free antiviral treatment in patients with indolent B-cell lymphomas associated with hepatitis C virus infection","volume":"126","author":"Arcaini","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2017.11.001_bib71","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1349-7006.2004.tb03256.x","article-title":"Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies","volume":"95","author":"Matsuo","year":"2004","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.beha.2017.11.001_bib72","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clml.2014.07.002","volume":"15","author":"Tarella","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T17:04:44Z","timestamp":1719594284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692617300786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1521692617300786"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2017.11.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overview on the management of non-gastric MALT lymphomas","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2017.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}